Dr. Martin Kolb, McMaster University, Hamilton, ON

IPF is a progressive disease with high morbidity and mortality. The past years have brought significant improvements in the pharmacological therapy of IPF, but disease progression nevertheless occurs in most patients, albeit at a slower rate. This means that symptomatic treatment of patients with IPF (and other fibrotic lung disorders) remains a major element of patient care.

Learning Objectives
At the end of this presentation, attendees will be able to:

  • Explain the unmet clinical need around PF-ILD;
  • Evaluate emerging evidence in PF-ILD treatments, specifically CTD-ILD; and
  • Discuss best practice approaches for collaborative care in the diagnosis and monitoring of CTD‑ILD.

This session is developed by the Canadian Thoracic Society with an independent educational grant from Boehringer Ingelheim.